期刊
JOURNAL OF EXPERIMENTAL MEDICINE
卷 204, 期 9, 页码 2131-2144出版社
ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20070070
关键词
-
资金
- NCI NIH HHS [R01 CA078846, CA 78846] Funding Source: Medline
- NIAID NIH HHS [U19 AI 057234-02, U19 AI057234] Funding Source: Medline
- NIAMS NIH HHS [R01 AR050770, R01 AR 050770-01] Funding Source: Medline
Systemic onset juvenile idiopathic arthritis ( SoJIA) represents up to 20% of juvenile idiopathic arthritis. We recently reported that interleukin ( IL) 1 is an important mediator of this disease and that IL-1 blockade induces clinical remission. However, lack of specificity of the initial systemic manifestations leads to delays in diagnosis and initiation of therapy. To develop a specific diagnostic test, we analyzed leukocyte gene expression profiles of 44 pediatric SoJIA patients, 94 pediatric patients with acute viral and bacterial infections, 38 pediatric patients with systemic lupus erythematosus ( SLE), 6 patients with PAPA syndrome, and 39 healthy children. Statistical group comparison and class prediction identified genes differentially expressed in SoJIA patients compared with healthy children. These genes, however, were also changed in patients with acute infections and SLE. An analysis of significance across all diagnostic groups identified 88 SoJIA-specific genes, 12 of which accurately classified an independent set of SoJIA patients with systemic disease. Transcripts that changed significantly in patients undergoing IL-1 blockade were also identified. Thus, leukocyte transcriptional signatures can be used to distinguish SoJIA from other febrile illnesses and to assess response to therapy. Availability of early diagnostic markers may allow prompt initiation of therapy and prevention of disabilities.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据